Celcuity Inc. (CELC)
NASDAQ: CELC · Real-Time Price · USD
74.00
-0.44 (-0.59%)
At close: Oct 29, 2025, 4:00 PM EDT
73.46
-0.54 (-0.73%)
After-hours: Oct 29, 2025, 7:15 PM EDT
Celcuity Employees
Celcuity had 87 employees as of December 31, 2024. The number of employees increased by 32 or 58.18% compared to the previous year.
Employees
87
Change (1Y)
32
Growth (1Y)
58.18%
Revenue / Employee
n/a
Profits / Employee
-$1,709,312
Market Cap
3.14B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 87 | 32 | 58.18% |
| Dec 31, 2023 | 55 | 10 | 22.22% |
| Dec 31, 2022 | 45 | 6 | 15.38% |
| Dec 31, 2021 | 39 | 9 | 30.00% |
| Dec 31, 2020 | 30 | 3 | 11.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CELC News
- 8 days ago - Celcuity: Updated Gedatolisib Data Bodes Well For Mutant-Type Cohort Results - Seeking Alpha
- 9 days ago - Celcuity Inc. (CELC) Discusses Additional Results From Phase III VIKTORIA-1 Trial and Insights Into PAM Pathway Targeting Transcript - Seeking Alpha
- 9 days ago - CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why - Invezz
- 11 days ago - Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer - GlobeNewsWire
- 11 days ago - Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”) - GlobeNewsWire
- 11 days ago - Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial - GlobeNewsWire
- 21 days ago - Celcuity: Blink And You Missed It - Seeking Alpha
- 5 weeks ago - Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress - GlobeNewsWire